Biomedical software company BostonGene Corporation announced on Tuesday that it has agreed a strategic collaboration with biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) to advance oncology drug development using BostonGene's multi-modal AI platform.

The partnership leverages BostonGene's foundation model for tumour and immune biology to predict patient-level safety and efficacy outcomes in early clinical trials. AstraZeneca will use these predictive insights to accelerate development timelines and mitigate risk across its oncology portfolio.

BostonGene's platform integrates pre-trained foundation models with multi-modal data analytics, including cell-free RNA and tumour microenvironment profiling. The approach aims to forecast treatment response and tolerability across diverse patient populations.

This initiative represents a key milestone in applying foundation models to real-world clinical development. The collaboration is intended to enable more adaptive, biomarker-informed oncology programmes.